Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
Vivos Therapeutics | 10-Q: Q2 2024 Earnings Report
Vivos Therapeutics | 424B1: Prospectus
Vivos Therapeutics | EFFECT: Others
Vivos Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Vivos Therapeutics | 10-K/A: Annual report (Amendment)
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Huntsman Ronald Kirk
Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SOKOLOW LEONARD J
Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thompson Matthew
Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Green Ralph Elias
Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Amman Bradford K.
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | 8-K: Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
Vivos Therapeutics | 10-Q: Q1 2024 Earnings Report
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | EFFECT: Others
Vivos Therapeutics | 424B1: Prospectus
No Data